Immune Checkpoint Inhibitor (PD-1)
|Title:||Immune Checkpoint Inhibitor (PD-1)|
Immune checkpoint inhibitor; the panel on the left shows the binding of proteins PD-L1 (on the tumor cell) to PD-1 (on the T cell), which keeps T cells from killing tumor cells in the body. Also shown are a tumor cell antigen and T cell receptor. The panel on the right shows immune checkpoint inhibitors (anti-PD-L1 and anti-PD-1) blocking the binding of PD-L1 to PD-1, which allows the T cells to kill tumor cells.
Immune checkpoint inhibitor. Checkpoint proteins, such as PD-L1 on tumor cells and PD-1 on T cells, help keep immune responses in check. The binding of PD-L1 to PD-1 keeps T cells from killing tumor cells in the body (left panel). Blocking the binding of PD-L1 to PD-1 with an immune checkpoint inhibitor (anti-PD-L1 or anti-PD-1) allows the T cells to kill tumor cells (right panel).
Cells or Tissue -- Abnormal Cells or Tissue
Treatment -- Immunotherapy
|Type:||Color, Medical Illustration (JPEG format)|
|Source:||National Cancer Institute|
|Creator:||Terese Winslow (Illustrator)|
|Date Created:||June 8, 2016|
|Date Added:||December 2, 2015|
Yes - This image is copyright protected. Any use of this image is subject to prevailing copyright laws. U.S. Government has reuse rights. Please contact the rights holder of this image for permission requests.
Rights holder: Terese Winslow